ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”), the medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, today announced its sponsorship of a symposium featuring four leading physicians who each plan to discuss their experience with BioSphere’s proprietary platform of interventional oncology embolic products. The symposium, entitled “New Embolization Therapies to Treat Liver Cancer,” along with additional scientific presentations by or regarding BioSphere and its products, will take place at this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting, which is being held September 8-12 in Athens, Greece.
